Trial
NCT02945046
A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Collaborators
—
Condition
Episodic Cluster Headache
Intervention
Fremanezumab
Why stopped
Study was terminated as a result of a pre-specified futility analysis at the interim of 150 participants completing the efficacy analysis of the study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-11-09